Antistreptococcal Activity of AR-709 Compared to That of Other Agents-Reference-Cited by-同舟云学术

Antistreptococcal Activity of AR-709 Compared to That of Other Agents

Published:2008-06 Issue:6 Volume:52 Page:2279-2282
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Smith Kathy¹,Ednie Lois M.¹,Appelbaum Peter C.¹,Hawser Stephen²,Lociuro Sergio²

Affiliation:

1. Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033

2. Arpida AG, Reinach, Switzerland

Abstract

ABSTRACT Against 300 strains of pneumococci and 100 group A streptococci of differing β-lactam, macrolide, and quinolone resistance phenotypes, AR-709 was very active, with all MICs being ≤2 μg/ml. Furthermore, AR-709 was active against strains that were both susceptible and resistant to trimethoprim-sulfamethoxazole.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01620-07

Reference26 articles.

1. Appelbaum, P. C. 1992. Antimicrobial resistance in Streptococcus pneumoniae—an overview. Clin. Infect. Dis.15:77-83.

2. Bozdogan, B., P. C. Appelbaum, L. Ednie, I. N. Grivea, and G. A. Syrogiannopoulos. 2003. Development of macrolide resistance by ribosomal protein L4 mutation in Streptococcus pyogenes during miocamycin treatment of an eight-year-old Greek child with tonsillopharyngitis. Clin. Microbiol. Infect.9:966-969.

3. Approved standard M100-S16. 2006

4. Cornaglia, G., M. Ligozzi, A. Mazzariol, L. Masala, G. L. Cascio, G. Orefici, R. Fontana, et al. 1998. Resistance of Streptococcus pyogenes to erythromycin and related antibiotics in Italy. Clin. Infect. Dis.27(Suppl. 1):S87-S92.

5. Antipneumococcal Activity of ABT-773 Compared to Those of 10 Other Agents

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitor design to target a unique feature in the folate pocket of Staphylococcus aureus dihydrofolate reductase;European Journal of Medicinal Chemistry;2020-08

2. Modified 2,4-diaminopyrimidine-based dihydrofolate reductase inhibitors as potential drug scaffolds against Bacillus anthracis;Bioorganic & Medicinal Chemistry;2015-01

3. A microdose study of 14C-AR-709 in healthy men: pharmacokinetics, absolute bioavailability and concentrations in key compartments of the lung;European Journal of Clinical Pharmacology;2013-06-06

4. Structure–activity relationship for enantiomers of potent inhibitors of B. anthracis dihydrofolate reductase;Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics;2013-01

5. Synthesis and biological activity of substituted 2,4-diaminopyrimidines that inhibit Bacillus anthracis;European Journal of Medicinal Chemistry;2012-08